Skip to content

Comparison of two treatment protocol in assisted reproductive techniques (ART) poor responders

Comparison between ultrashort gonadotropin-releasing hormone agonist and flare microdose protocol in ART poor responders

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201105096420N1
Enrollment
120
Registered
2011-06-06
Start date
2007-06-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility. Female infertility

Interventions

Intervention 1: In group I, 0.05mg subcutaneous Buserelin (suprefact, serono) was injected two times per day from the day 1 of cycle and HMG (Menogon, Ferring) 300 IU per day intramuscular from day 3
NV organon, oss, Netherlands) 10000 IU was injectod Intramuscular when at least 2 follicles = 18mm were noted on ultrasonography. Oocyte retrieval was scheduled 36 hours after hCG injection and conven
Treatment - Drugs
In group I, 0.05mg subcutaneous Buserelin (suprefact, serono) was injected two times per day from the day 1 of cycle and HMG (Menogon, Ferring) 300 IU per day intramuscular from day 3 of cycle. Follic
In group II, ovulation induction was performed with Buserelin (suprefact, serono) 0.5mg SC per day started on day 1 of cycle and continued for 3 consecutive days . HMG (menogon, ferring) 300 IU per da

Sponsors

Yazd Research and Clinical Center for Infertility
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: A history of one or more failed in IVF cycles which three or fewer oocytes were been retrieved or their serum steradiol’s level in day of HCG injection was 10 or age>40 years. Exclusion criteria: Body mass index higher than 30 and endocrine or metabolic disorder, endometriosis and severe male factor (azospermia ).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pregnancy. Timepoint: 2 weeks. Method of measurement: BhcG Test.

Secondary

MeasureTime frame
Number of follicles. Timepoint: 15 days. Method of measurement: Numbering.;Quality of oocytes. Timepoint: 15 days. Method of measurement: Observation by microscope according to Good –postmature-degenerated.;The number of used gonadotropin ampoules. Timepoint: 15 days. Method of measurement: Numbering.;Quality of emberyo. Timepoint: 15 days. Method of measurement: According to the symmetrics and exact of Blastomer pieces.;Number of oocytes. Timepoint: 15 days. Method of measurement: Numbering.;Chemical pregnancy. Timepoint: after 14 days of embryo transfer. Method of measurement: Measurement of serum B-hCG.;Clinical pregnancy. Timepoint: 2-3 weeks after positive B-hCG. Method of measurement: observation of the fetal heart activity using a transvaginal ultrasonography.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Maryam Eftekhar

Research and Clinical Center for Infertility

eftekhar@ssu.ac.ir , pkhani55@gmail.com+98 35 1824 7348

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026